Literature DB >> 17674348

Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer.

G G Van den Eynden1, I Van der Auwera, S J Van Laere, X B Trinh, C G Colpaert, P van Dam, L Y Dirix, P B Vermeulen, E A Van Marck.   

Abstract

Angiogenesis and lymphangiogenesis are complex processes, driven by multiple factors. In primary breast tumours (PTs), VEGFA, -C and -D are the most important (lymph)angiogenic factors. The induction of lymphangiogenesis in axillary lymph node (LN) metastases of patients with breast cancer was described recently. To compare the molecular determinants of (lymph)angiogenesis in LN metastases and PTs of breast cancer patients, RNA was isolated from formalin-fixed, paraffin-embedded tissue sections of a metastatically involved and uninvolved LN and the PT from 26 lymph node-positive patients. The expression of 12 (lymph)angiogenic markers was measured by qRT-PCR. Expression was correlated with tumour cell proliferation, angiogenesis and lymphangiogenesis, quantified by tumour cell proliferation fraction (TCP%) and (lymphatic) endothelial cell proliferation fraction [(L)ECP%]. TCP%, ECP% and LECP% were assessed on immunohistochemical double stains for CD34/Ki-67 and D2-40/Ki-67, respectively. In involved LNs, the relative gene expression levels of PROX1 (p < 0.001) and FGF2 (p = 0.008) were decreased and the expression levels of VEGFA (p = 0.01) and PDGFB (p = 0.002) were increased compared to uninvolved LNs. The expression of most markers was increased in PTs compared to involved LNs. In metastatically involved LNs, the expression of VEGFA correlated with ECP% (r = 0.54, p = 0.009) and LECP% (r = 0.76, p < 0.001). In PTs, VEGFA correlated only with ECP% (r = 0.74, p < 0.001). VEGFD correlated with peritumoural LECP% (r = 0.61, p = 0.001) and with VEGFC (r = 0.78, p < 0.001). Linear regression analysis confirmed the expression of VEGFA as an independent predictor of ECP% in both PTs and LN metastases and of LECP% in LN metastases. The expression of VEGFD, but not of VEGFA, independently predicted peritumoural LECP% in PTs. Our results confirm existing data that, in PTs, angiogenesis and lymphangiogenesis are respectively driven by VEGFA and VEGFD. In contrast, in LN metastases, both processes seem to be driven by VEGFA. Lymphangiogenesis in PTs and in LN metastases might thus be driven by different factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674348     DOI: 10.1002/path.2211

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

1.  The type of metastasis is a prognostic factor in disseminated cervical cancer.

Authors:  Kidong Kim; Soo Youn Cho; Beob-Jong Kim; Moon-Hong Kim; Seok-Cheol Choi; Sang-Young Ryu
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Lymphangiogenesis in breast cancer is associated with non-sentinel lymph node metastases in sentinel node positive patients.

Authors:  Lin Lv; Rui-Min Ma; Fan Yang; Xiao-Hua Zhang; Du-Ping Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Myeloid-Derived Lymphatic Endothelial Cell Progenitors Significantly Contribute to Lymphatic Metastasis in Clinical Breast Cancer.

Authors:  Lisa Volk-Draper; Radhika Patel; Nihit Bhattarai; Jie Yang; Andrew Wilber; David DeNardo; Sophia Ran
Journal:  Am J Pathol       Date:  2019-08-15       Impact factor: 4.307

4.  Can lymphatic vascular density be used in determining metastatic spreading potential of tumor in invasive ductal carcinomas?

Authors:  Nilufer Onak Kandemir; Figen Barut; Sibel Bektas; Sukru Oguz Ozdamar
Journal:  Pathol Oncol Res       Date:  2011-07-23       Impact factor: 3.201

5.  VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer.

Authors:  X Bich Trinh; P A van Dam; P B Vermeulen; S J Van Laere; G G Van den Eynden; W A A Tjalma; L Y Dirix
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

6.  Fluorescence in situ hybridization markers for prediction of cervical lymph node metastases.

Authors:  Darawalee Wangsa; Kerstin Heselmeyer-Haddad; Patricia Ried; Elina Eriksson; Alejandro A Schäffer; Larry E Morrison; Juhua Luo; Gert Auer; Eva Munck-Wikland; Thomas Ried; Elisabeth Avall Lundqvist
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

7.  Lymphangiogenesis and lymphatic metastasis in breast cancer.

Authors:  Sophia Ran; Lisa Volk; Kelly Hall; Michael J Flister
Journal:  Pathophysiology       Date:  2009-12-24

8.  In vivo "MRI phenotyping" reveals changes in extracellular matrix transport and vascularization that mediate VEGF-driven increase in breast cancer metastasis.

Authors:  Arvind P Pathak; Stephen McNutt; Tariq Shah; Flonne Wildes; Venu Raman; Zaver M Bhujwalla
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

9.  The -553 T/A polymorphism in the promoter region of the FGF2 gene is associated with increased breast cancer risk in Polish women.

Authors:  Jan Rykala; Karolina Przybylowska; Ireneusz Majsterek; Grazyna Pasz-Walczak; Andrzej Sygut; Adam Dziki; Piotr Kuna
Journal:  Arch Med Sci       Date:  2014-01-23       Impact factor: 3.318

10.  The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.

Authors:  Helena Linardou; Konstantine T Kalogeras; Ralf Kronenwett; George Kouvatseas; Ralph M Wirtz; Flora Zagouri; Helen Gogas; Christos Christodoulou; Angelos K Koutras; Epaminondas Samantas; Dimitrios Pectasides; Dimitrios Bafaloukos; George Fountzilas
Journal:  Breast Cancer Res       Date:  2012-11-12       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.